Pulse Biosciences (NASDAQ: PLSE) CCO sells shares after exercising options

Rhea-AI Filing Summary

Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of $1.53 per share each day, converting them into 20,000 common shares per day.

On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of $21.45, $23.52, and $25.20 per share, respectively, leaving 43,298 common shares held directly after each day’s sale. These trades were carried out under a Rule 10b5‑1 trading plan adopted on May 14, 2025.

Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of $1.53 per share, originally granted on September 23, 2022 for up to 450,000 shares, with 25% vesting on each anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Danahy Kevin Patrick

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/09/2026		S(1)		20,000	D	$21.45(2)	43,298	D
Common Stock	02/10/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/10/2026		S(1)		20,000	D	$23.52(3)	43,298	D
Common Stock	02/11/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/11/2026		S(1)		20,000	D	$25.2(4)	43,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.53	02/09/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	405,000	D
Stock Option (right to buy)	$1.53	02/10/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	385,000	D
Stock Option (right to buy)	$1.53	02/11/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	365,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

2. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $21.00 to $23.22 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

3. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $26.08 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

4. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.36 to $26.36 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

5. Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PLSE’s Chief Commercial Officer report?

Kevin Patrick Danahy exercised stock options and sold common shares in Pulse Biosciences. Over February 9–11, 2026, he exercised 20,000 options per day at $1.53 and sold 20,000 shares per day in open-market transactions at progressively higher weighted average prices.

At what prices did the PLSE insider sell common stock?

The reported sales used weighted average prices per share. On February 9, 10, and 11, 2026, Kevin Patrick Danahy sold 20,000 Pulse Biosciences shares each day at $21.45, $23.52, and $25.20, respectively, as disclosed in the Form 4 transaction table.

How many PLSE common shares does the insider hold after these trades?

After each day’s reported transactions, Kevin Patrick Danahy directly beneficially owned 43,298 shares of Pulse Biosciences common stock. This figure reflects his holdings following the exercise of 20,000 options and the sale of 20,000 shares on each of the three transaction dates.

What stock options in PLSE does the Chief Commercial Officer still own?

Following the option exercises, Kevin Patrick Danahy directly holds 365,000 stock options for Pulse Biosciences common stock. These options have a $1.53 exercise price, were granted on September 23, 2022, and were originally for up to 450,000 shares with annual 25% vesting.

Were the PLSE insider trades under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that all the reported transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Kevin Patrick Danahy on May 14, 2025, and pre-arranged the timing and amounts of his trades in Pulse Biosciences shares.

What do the weighted average prices in the PLSE Form 4 mean?

The prices reported for the sales are weighted average prices per share. Footnotes explain that actual sale prices ranged within specified bands and that, upon request, the insider will provide detailed breakdowns of the number of shares sold at each individual price within those ranges.